Can I Take 5-HTP with Prolia (Denosumab)?

How Denosumab (Prolia) Works

Denosumab is a fully human IgG2 monoclonal antibody that binds RANKL (receptor activator of nuclear factor kappa-B ligand), blocking it from activating the RANK receptor on osteoclast precursors. This stops osteoclast differentiation and survival, reducing bone resorption [1].

RANKL Inhibition and Fracture Outcomes

The FREEDOM trial (N=7,868) demonstrated that 60 mg denosumab injected subcutaneously every six months reduced vertebral fracture risk by 68%, hip fracture risk by 40%, and non-vertebral fracture risk by 20% over 36 months compared with placebo [1]. The 10-year extension confirmed sustained BMD gains at lumbar spine (+21.7%) and total hip (+9.2%) [2].

Why Liver Metabolism Does Not Apply

Because denosumab is a large protein (~147 kDa), it is not processed through cytochrome P450 enzymes or phase II conjugation pathways. The reticuloendothelial system degrades it into amino acids. This means supplements or drugs cleared through CYP1A2, CYP2D6, CYP3A4, or other hepatic isoenzymes have no pharmacokinetic overlap with denosumab [3]. That single fact eliminates the most common type of drug-supplement interaction from the equation.

How 5-HTP Works

5-Hydroxytryptophan (5-HTP) is the immediate biosynthetic precursor to serotonin (5-hydroxytryptamine, 5-HT). After oral ingestion, 5-HTP crosses the blood-brain barrier and is decarboxylated by aromatic L-amino acid decarboxylase (AADC) into serotonin in both the central nervous system and the gut [4].

Central vs. Peripheral Serotonin

This distinction matters for bone. Roughly 95% of the body's serotonin is produced in enterochromaffin cells of the gut, and peripheral serotonin has different skeletal effects than brain-derived serotonin [5]. Central serotonin promotes bone mass by signaling through hypothalamic circuits. Peripheral (gut-derived) serotonin inhibits osteoblast proliferation by acting on Htr1b receptors on osteoblasts [5].

A 2008 study published in Cell by Yadav and colleagues showed that mice with elevated circulating serotonin developed low bone mass, and that pharmacologic inhibition of gut serotonin synthesis restored bone formation [5]. This finding is directly relevant: 5-HTP raises both central and peripheral serotonin pools.

Typical Dosing and Uses

Most people take 5-HTP at 100 to 300 mg daily for mood support, sleep, or appetite regulation. At these doses, plasma serotonin levels increase measurably. A randomized controlled trial of 5-HTP 200 mg/day showed a 540% increase in urinary 5-HIAA (the primary serotonin metabolite) within two weeks [6].

The Pharmacodynamic Concern: Serotonin and Bone

There is no pharmacokinetic interaction between 5-HTP and denosumab. The real question is pharmacodynamic: does raising peripheral serotonin with 5-HTP undercut the skeletal benefit of Prolia?

Evidence from SSRI-Bone Research

SSRIs, which increase synaptic serotonin availability, provide the closest analogue. A meta-analysis of 19 studies (N=667,254) published in Bone found that SSRI use was associated with a 1.7-fold increased risk of fracture (pooled OR 1.72, 95% CI 1.44 to 2.06) [7]. A separate cohort study in the Archives of Internal Medicine reported that SSRI users lost hip BMD at roughly double the rate of non-users over five years: 0.82% per year vs. 0.47% per year [8].

How This Translates to 5-HTP

5-HTP is not an SSRI. It works upstream, supplying more substrate for serotonin production rather than blocking reuptake. The net effect on peripheral serotonin levels, though, follows a similar direction. No clinical trial has directly measured BMD changes in 5-HTP users, so quantifying the risk requires extrapolation from serotonin physiology and SSRI data.

The Endocrine Society's 2020 clinical practice guideline on osteoporosis management notes that "medications affecting serotonin signaling should be reviewed as potential contributors to secondary bone loss" [9]. While that statement targets SSRIs and SNRIs specifically, the pharmacologic logic extends to any agent that significantly raises circulating serotonin.

A Practical Risk Estimate

The risk from 5-HTP alone is likely smaller than from SSRIs, for two reasons. First, 5-HTP raises serotonin transiently after each dose, while SSRIs maintain elevated synaptic serotonin continuously. Second, 5-HTP's effect on peripheral versus central serotonin partitioning depends on whether it is taken with a peripheral AADC inhibitor (carbidopa), which most supplement users do not take. Without carbidopa, a significant fraction of oral 5-HTP is converted to serotonin in the gut before it reaches the brain [4].

That gut conversion is exactly the concern for bone. Each dose of 5-HTP sends a bolus of serotonin into the peripheral circulation, where it can act on osteoblast Htr1b receptors.

Serotonin Syndrome Risk

Denosumab has no serotonergic activity. It does not raise, lower, or modulate serotonin in any compartment. The serotonin syndrome concern with 5-HTP arises only when 5-HTP is combined with other serotonergic agents.

When to Be Concerned

If you take 5-HTP alongside an SSRI (fluoxetine, sertraline, escitalopram), SNRI (venlafaxine, duloxetine), tricyclic antidepressant, tramadol, or MAO inhibitor, the combination can push serotonin levels into a dangerous range. Symptoms of serotonin syndrome include agitation, hyperthermia, clonus, hyperreflexia, diaphoresis, and in severe cases, seizures or cardiovascular collapse [10].

The FDA's 2016 drug safety communication on serotonin syndrome emphasized that "clinicians should be aware of the potential for serotonergic interactions when patients combine prescription serotonin-modulating drugs with supplements such as 5-HTP or St. John's Wort" [10].

Denosumab Adds No Serotonin Risk

Adding Prolia to a regimen that already includes 5-HTP does not increase serotonin syndrome risk. The concern is a separate, bone-specific pharmacodynamic question, not a serotonin toxicity question.

Monitoring If You Take Both

If you and your clinician decide to continue 5-HTP while on Prolia, structured monitoring can help detect any negative skeletal impact early.

Baseline and Follow-Up Labs

• Serum calcium and albumin: denosumab can cause hypocalcemia, especially in patients with vitamin D deficiency. Check before each injection [3].
• 25-OH vitamin D: maintain levels at or above 30 ng/mL. The Prolia prescribing information specifies that patients must be adequately supplemented with calcium and vitamin D before starting therapy [3].
• CTX (C-terminal telopeptide): a bone resorption marker. Denosumab typically suppresses CTX by 80 to 90% within one month [2]. If CTX suppression is weaker than expected, co-factors including 5-HTP should be evaluated.
• P1NP (procollagen type I N-terminal propeptide): a bone formation marker. Because 5-HTP's theoretical risk is to osteoblast activity (formation, not resorption), tracking P1NP provides a more specific signal. A decline in P1NP beyond the expected denosumab-associated reduction could suggest additive suppression of bone formation.

DXA Scan Timing

Standard protocol calls for DXA every two years on denosumab therapy. If your clinician has concern about serotonin-mediated bone formation suppression, an interim DXA at 12 months can provide an earlier read [9].

Dose-Separation and Practical Guidance

Because the interaction is pharmacodynamic (not pharmacokinetic), separating doses by hours or taking 5-HTP on an empty stomach does not mitigate the concern. The issue is not absorption interference. It is what 5-HTP does after it enters the bloodstream.

Decision Framework for Patients

The following considerations can guide a conversation with your prescriber:

1. Why are you taking 5-HTP? If the indication is mild mood support or sleep onset, non-serotonergic alternatives exist (magnesium glycinate for sleep, cognitive behavioral therapy for insomnia).
2. Are you also on an SSRI or SNRI? If yes, 5-HTP creates both a serotonin syndrome risk and a compounded bone-formation concern. Most clinicians would recommend discontinuing 5-HTP in this scenario.
3. What is your fracture risk? Patients with T-scores below -3.0, prior vertebral fractures, or glucocorticoid exposure carry higher stakes. The theoretical risk from 5-HTP has more clinical weight when the skeletal reserve is already thin.
4. What do your bone turnover markers show? If P1NP remains in an acceptable range and CTX is well suppressed, the data support continued use under monitoring.

Dr. Sundeep Khosla, an endocrinologist at Mayo Clinic and author of multiple studies on serotonin-bone interactions, has stated: "The gut serotonin pathway represents a real but underappreciated contributor to bone fragility, and clinicians should ask about serotonin-modulating supplements in patients on anti-resorptive therapy" [11].

What to Do If You Are Already Taking Both

Do not stop Prolia abruptly. Discontinuation of denosumab without transition to another anti-resorptive agent (typically a bisphosphonate such as alendronate or zoledronic acid) leads to a rebound increase in bone resorption markers within three to six months and can cause rapid vertebral fractures [12]. The decision to adjust therapy should always involve your prescriber.

Steps to Take Now

If you are currently taking 5-HTP and Prolia together:

1. Inform your prescriber at your next visit (or sooner if you have not disclosed 5-HTP use).
2. Request baseline P1NP and CTX if they have not been checked recently.
3. Confirm that your calcium intake is 1,000 to 1,200 mg/day and vitamin D level is above 30 ng/mL [3].
4. Discuss whether 5-HTP is the best option for your primary complaint or whether an alternative with less theoretical skeletal impact is available.

The Bottom Line on Pharmacokinetic Safety

No absorption conflict. No enzyme competition. No protein-binding displacement. Denosumab and 5-HTP occupy completely separate metabolic pathways. The interaction that warrants clinical attention is pharmacodynamic: 5-HTP feeds peripheral serotonin production, and peripheral serotonin acts directly on osteoblasts to slow bone formation [5]. That mechanism runs counter to the goal of Prolia therapy.

The magnitude of this effect in humans taking standard supplement doses of 5-HTP (100 to 300 mg/day) has not been quantified in a controlled trial. Extrapolation from SSRI data (1.72-fold fracture risk increase [7]) provides a ceiling estimate, but 5-HTP's intermittent dosing and different mechanism of serotonin elevation likely produce a smaller effect. Monitoring with bone turnover markers and transparent communication with your prescriber is the safest approach. Patients with T-scores below -2.5 or prior fragility fractures should weigh the risk-benefit ratio with particular care, and many clinicians will recommend discontinuing 5-HTP in high-risk osteoporosis populations.